MIB1 and meningioma: Univariable analysis using independent t-test revealed that patients with an MIB-I labeling index ≥ 9% (determined in the recurrent tumor tissue) had a significantly shorter time to meningioma recurrence (27.6 ± 16.0 months), compared to the patients with an MIB-1 labeling index < 9% (53.6 +/− 28.8 months) (p = 0.04).